Lonza to sell capsules & health ingredients business for $3 billion in major strategic shift

Roche’s Gazyva shows breakthrough results in Lupus phase III trial

Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints

Merck delivers resilient 2025 performance despite global headwinds

Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results

CordenPharma expands boulder presence with 64,000-Sq-Ft Lease at BioMed Realty’s Flatiron Park

The new LEED Gold-certified building will serve as CordenPharma Colorado’s sole tenant

argenx reports breakthrough Phase 3 results for VYVGART in ocular myasthenia gravis

The trial met its primary endpoint, showing statistically significant improvements in Myasthenia Impairment Index (MGII) Patient-Reported Outcome (PRO) ocular scores at Week 4

FDA okays JUXTAPID for kids with ultra-rare genetic cholesterol disorder

Granules India’s US packaging facility clears FDA inspection with zero observations

The inspection concluded with zero observations, confirming the facility's compliance with current Good Manufacturing Practices

Esperion to acquire Corstasis, gaining first FDA-approved nasal spray Diuretic

Univar Solutions bags exclusive US & Canada deal for Ingredion Pharmaceutical starches

AbbVie’s Risankizumab shows strong results in hard-to-treat Crohn’s disease patients

This study evaluated a difficult-to-treat Crohn's disease patient population